SCHEMBL3826784

SCHEMBL3826784

FC(F)(F)c1ccc2c(Cl)cc(C(F)(F)F)nc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NT5E P21589 2/20 0.54
C1R P00736 1/20 0.46
KDM4E B2RXH2 2/20 0.42
PARP1 P09874 1/20 0.41
LMNA P02545 1/20 0.41
F7 P08709 1/20 0.40
F3 P13726 1/20 0.40
BACE1 P56817 1/20 0.39
KIF20B Q96Q89 1/20 0.38
PDE2A O00408 1/20 0.38
IGF1R P08069 1/20 0.37
PRKD3 O94806 1/20 0.37
MAP4K4 O95819 1/20 0.37
MARK3 P27448 1/20 0.37
KDR P35968 1/20 0.37
MAPKAPK2 P49137 1/20 0.37
GSK3A P49840 1/20 0.37
GSK3B P49841 1/20 0.37
PRKCZ Q05513 1/20 0.37
PRKAA1 Q13131 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9493411 0.90 NT5E (0.51) NT5EC1RKDM4EPARP1LMNA
SCHEMBL9493259 0.90 C1R (0.50) NT5EC1RKDM4EPARP1LMNA
SCHEMBL2709353 0.86 NT5E (0.68) NT5EKDM4ELMNABACE1PDE2A
SCHEMBL31327779 0.86 NT5E (0.68) NT5EKDM4ELMNABACE1PDE2A
SCHEMBL23066252 0.86 C1R (0.46) NT5EC1RKDM4EPARP1LMNA
SCHEMBL8396844 0.84 C1R (0.45) NT5EC1RKDM4EPARP1LMNA
SCHEMBL3344697 0.84 NT5E (0.56) NT5EKDM4ELMNAIGF1RGSK3A
SCHEMBL900362 0.83 MAPT (0.51) C1RKDM4EPARP1LMNAF7
SCHEMBL3850835 0.81 BACE1 (0.45) NT5EKDM4EPARP1LMNAF7
SCHEMBL3828474 0.81 BACE1 (0.45) NT5EKDM4EPARP1LMNAF7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017136642-A1 ANTIBIOTIC COMPOSITIONS THE TRUSTEES OF DARTMOUTH COLLEGE (US) 2017-08-10 WO disclosed
EP-1567477-B1 SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS NOVARTIS AG (CH) 2009-09-09 EP disclosed
EP-2090566-A2 Certain phenylacetic acids and derivatives Novartis AG (CH) 2009-08-19 EP disclosed
US-7202364-B2 Certain phenylacetic acids and derivatives NOVARTIS, AG (CH) 2007-04-10 US disclosed
EP-1567477-A1 SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS Novartis AG (CH) 2005-08-31 EP disclosed
US-20040132769-A1 Certain phenylacetic acids and derivatives NOVARTIS AG (CH) 2004-07-08 US disclosed
WO-2004048314-A1 SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS NOVARTIS AG (CH) 2004-06-10 WO disclosed
EP-0111329-B1 FLUOROMETHYL QUINOLINE DERIVATIVES AND THEIR PREPARATION ALKALOIDA VEGYESZETI GYAR (HU) 1989-03-15 EP disclosed
US-4659834-A Process for the preparation of fluoromethyl-quinoline derivatives ALKALOIDA VEGYESZETI GYAR (HU) 1987-04-21 US disclosed
EP-0111329-A1 Fluoromethyl quinoline derivatives and their preparation ALKALOIDA VEGYESZETI GYAR (HU) 1984-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132769-A1 Certain phenylacetic acids and derivatives CYP2A6, HCAR2, CYP2B6 NT5E 3158/4885C1R 1521/4885KDM4E 3616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.